$0.00
0.00%
Nasdaq, Aug 08, 03:30 pm CET
ISIN
US6404421090
Symbol
NMRD

NEMAURA MEDICAL INC Stock price

$0.00
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
-0.03 99.71% 1Y
-2.38 100.00% 3Y
-5.46 100.00% 5Y
-11.00 100.00% 10Y
-2.50 100.00% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.00 0.00%

Key metrics

Basic
Market capitalization
$0.0
Enterprise Value
$19.5m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 0.0
P/S
- | 0.0
EV/Sales
- | 95.6
EV/FCF
negative
P/B
0.0
Financial Health
Equity Ratio
-81.1%
Return on Equity
119.7%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $204.0k
EBITDA
- | -
EBIT
- | $-7.5m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | 155.0%
EBITDA
- | -
EBIT
- | -5.7%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
0.3%
Employees
36
Rev per Employee
$0.0
Show more

Is NEMAURA MEDICAL INC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

NEMAURA MEDICAL INC Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a NEMAURA MEDICAL INC forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a NEMAURA MEDICAL INC forecast:

Buy
86%
Hold
14%

Financial data from NEMAURA MEDICAL INC

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.59 5.59
14% 14%
-
- Research and Development Expense 1.89 1.89
22% 22%
-
-9.46 -9.46
60% 60%
-
- Depreciation and Amortization 0.48 0.48
33% 33%
-
EBIT (Operating Income) EBIT -9.94 -9.94
58% 58%
-
Net Profit -11 -11
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about NEMAURA MEDICAL INC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Through its subsidiaries, it manufactures and commercializes continuous glucose monitoring system, named sugarBEAT. The sugarBEAT is consist of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in Loughborough, the United Kingdom.

Head office United States
CEO Dewan Chowdhury
Employees 36
Founded 2013
Website nemauramedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today